Prostate Cancer: Surgery or SBRT — Which Is the Better Treatment?
For men with localised prostate cancer, choosing between surgery and SBRT (stereotactic body radiation therapy) is one of the most common and genuinely difficult treatment decisions. For appropriate candidates, both approaches achieve similar long-term cancer control rates — but they carry different side effect profiles, recovery timelines, and quality-of-life implications. There is no universally "better" option; the right choice depends on individual clinical and personal factors.
Quick summary
- Both surgery and SBRT can effectively treat localised low-to-intermediate risk prostate cancer
- Surgery removes the prostate; SBRT destroys tumour cells with precisely targeted high-dose radiation over 5 sessions
- The side effect profiles differ significantly — particularly for urinary control and erectile function
- Neither approach is universally superior; patient-specific factors determine which is more appropriate
- An MDT review with both a urological surgeon and a radiation oncologist is advisable before deciding
What Surgery and SBRT Actually Involve
SRadical Prostatectomy (Surgery)
Surgical removal of the entire prostate gland and seminal vesicles. Performed as open surgery, laparoscopic surgery, or robotic-assisted surgery (RALP — robot-assisted laparoscopic prostatectomy, commonly using the da Vinci system).
- Treatment is delivered in a single operation
- Provides definitive pathological staging (confirms margin status, lymph node involvement)
- PSA drops to undetectable level within 6–8 weeks if successful
- Salvage radiation remains possible if surgical margins are positive
- General anaesthesia required; hospital stay typically 1–3 days
- Recovery to normal activity: 4–6 weeks
RSBRT / SABR (Stereotactic Body Radiation Therapy)
Precisely targeted high-dose radiation delivered in a small number of fractions — typically 5 sessions over 1–2 weeks — using advanced image guidance. Also called SABR (stereotactic ablative radiotherapy) or, when delivered with a CyberKnife system, robotic radiosurgery.
- Non-surgical; no anaesthesia required
- Typically 5 sessions; shorter overall treatment course than conventional radiotherapy (35–44 fractions)
- Each session lasts approximately 30–60 minutes
- No overnight hospital stay required
- PSA decline is gradual over months after treatment
- Salvage surgery is technically possible but complex if radiation fails
SBRT for prostate cancer should be distinguished from conventional external beam radiotherapy (IMRT, VMAT), which involves 35–44 fractions over 7–9 weeks and is a separate modality. SBRT condenses this into 5 high-dose fractions, with comparable or non-inferior disease control demonstrated in clinical trials including PACE-B.
Cancer Control: Are the Outcomes Equivalent?
For localised low-to-intermediate risk prostate cancer, the oncological evidence suggests that surgery and radiation therapy (including SBRT) achieve similar long-term cancer control. No randomised trial has convincingly demonstrated that either approach leads to better survival — and for most patients with localised disease, treatment choice is driven by side effect profile, not by meaningful differences in cancer control.
What the evidence shows:
- Localised low-intermediate risk: Both surgery and SBRT are guideline-endorsed options. Disease control rates are similar across 10-year follow-up in multiple cohort studies and meta-analyses.
- High-risk localised prostate cancer: High-risk disease often requires multimodal treatment — radiation plus androgen deprivation therapy (ADT), or surgery with adjuvant or salvage radiotherapy. SBRT alone is generally not the primary approach for high-risk disease.
- Locally advanced or metastatic disease: Neither surgery nor SBRT alone is typically the primary strategy. ADT, systemic therapy, and combinations are usually indicated — sometimes with radiation to the prostate or to oligometastatic sites.
For international patients who have received a recommendation for one approach without a thorough MDT discussion, a structured second opinion that includes both urological oncology and radiation oncology perspectives is a reasonable first step before committing to a specific modality.
Side Effects: The Key Differences Between Surgery and SBRT
This is where surgery and SBRT differ most meaningfully — and where individual circumstances matter most. Understanding the side effect profile of each approach is central to making an informed decision.
| Side effect | Surgery | SBRT |
|---|---|---|
| Urinary incontinence | Common immediately after surgery; majority recover within 3–12 months. Depends on nerve preservation and baseline continence. | Rare as a long-term outcome. Acute urinary symptoms (frequency, urgency, dysuria) during and shortly after treatment are common but usually resolve. |
| Erectile dysfunction | Immediate after surgery. Recovery depends on nerve-sparing technique, age, baseline function. Rehabilitation (PDE5 inhibitors, vacuum device) may help. Full recovery takes months to years. | More gradual onset — often 12–18+ months after treatment. Overall rates similar to surgery at 5 years but timing differs significantly. |
| Bowel side effects | Minimal; the rectum is not directly in the radiation field. | Rectal irritation, diarrhoea, rectal bleeding (rare). Risk depends on rectal dosimetry and patient anatomy. Gel spacer insertion (SpaceOAR) reduces rectal dose. |
| Recovery time | 4–6 weeks to return to normal activities; pelvic floor exercises required. | No significant post-treatment recovery period required; patients can resume normal activities between sessions. |
| Treatment duration | Single procedure, 2–4 hour operation | 5 sessions over 1–2 weeks (each ~30–60 minutes) |
| Anaesthetic risk | General anaesthesia required; relevant for older or less fit patients. | No anaesthesia; suitable for patients with surgical contraindications. |
Uncertain between surgery and SBRT for your prostate cancer?
A structured case review with both a urological oncology and radiation oncology perspective — before committing to one approach — can clarify which option is most appropriate for your specific risk group, anatomy, and priorities.
Request a case reviewWhat Factors Guide the Choice Between Surgery and SBRT?
The following factors are typically assessed by a multidisciplinary team when evaluating which approach is most appropriate for an individual patient. No single factor determines the decision — they are considered together.
Risk classification and biopsy findings
Gleason score (Grade Group), PSA level and PSA density, number of positive biopsy cores, percentage of core involvement, and MRI features (extraprostatic extension, seminal vesicle involvement) together define risk group. Low and intermediate risk disease is more readily treated with either modality. High-risk disease typically warrants combined modality discussion.
Age and surgical fitness
Radical prostatectomy requires general anaesthesia and carries perioperative risks that increase with age and comorbidities. For older patients or those with cardiac, pulmonary, or anaesthetic contraindications, SBRT avoids surgical risk entirely.
Baseline urinary symptoms
Men with significant pre-existing lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH) may experience worsening of symptoms acutely after SBRT. For these patients, surgery — which removes the obstructing gland — may relieve urinary symptoms rather than worsen them.
Baseline erectile function
For men who place high priority on preserving erectile function, both approaches carry significant risk — but the timing and nature of erectile dysfunction differs. The ability to perform nerve-sparing surgery (determined by tumour location), baseline erectile function, and patient age all influence this discussion.
Prostate volume and anatomy
A very large prostate volume may be a relative contraindication for SBRT because of dosimetry challenges. Conversely, a technically difficult anatomy (prior pelvic surgery, adhesions) may make surgery more complex.
Desire for definitive pathological staging
Surgery provides a pathological specimen — allowing definitive assessment of surgical margins, lymph node involvement, and final Gleason grade. For some patients, particularly those with intermediate-high risk features, having this information to guide further treatment decisions is a significant advantage of surgery.
Lifestyle and treatment burden preference
For patients who prefer a non-surgical, shorter treatment course without a recovery period — particularly those who travel long distances — SBRT's 5-session schedule is logistically more manageable. Surgery requires a longer local stay, post-operative care, and catheter management.
When Prostate Cancer Requires More Than Surgery or SBRT Alone
Some patients with prostate cancer have disease characteristics that make either surgery or SBRT alone insufficient as a single treatment. Recognising these situations is important before committing to a single-modality plan.
High-risk localised prostate cancer
High-risk features (PSA >20, Gleason Grade Group 4–5, clinical stage T3) typically require radiation combined with long-course ADT (androgen deprivation therapy), or surgery with planned adjuvant or salvage radiation. SBRT alone is generally not standard for high-risk localised disease.
Lymph node involvement (N1 disease)
If imaging or pathology confirms pelvic lymph node involvement, the treatment strategy changes significantly — typically incorporating systemic therapy (ADT plus possibly docetaxel or novel androgen receptor pathway inhibitors) alongside local treatment.
Oligometastatic prostate cancer
A distinct use case for SBRT: delivering stereotactic ablative radiation to a small number of metastatic sites (oligometastatic disease) while systemic therapy addresses the broader disease. This is not the same as using SBRT to treat the primary prostate tumour.
Positive surgical margins after prostatectomy
If pathological staging after surgery reveals positive margins or other adverse features, adjuvant or salvage radiotherapy may be recommended. Understanding this possibility before surgery — and how it would be managed — is part of informed pre-operative planning.
Understanding which treatment category a specific case falls into requires a thorough review of PSA history, biopsy pathology, mpMRI findings, and staging scans. The treatment-by-stage guide covers how prostate cancer management changes across localised, locally advanced, and metastatic presentations.
Prostate Cancer Treatment in China: What International Patients Should Know
China's large tertiary cancer centres are experienced in both robotic-assisted radical prostatectomy (da Vinci RALP) and SBRT/SABR for prostate cancer. Prostate cancer incidence in China has risen significantly over the past two decades as PSA testing has become more widespread, and major urological oncology and radiation oncology departments see substantial caseloads.
International patients considering prostate cancer treatment in China benefit from understanding which centres have specific experience in their required modality. Cancer treatment coordination support can help identify appropriate centres and navigate the pre-treatment evaluation process.
Supportive Care During Prostate Cancer Treatment
Both surgery and SBRT for prostate cancer involve a period of recovery and adjustment — and for patients receiving long-course androgen deprivation therapy alongside radiotherapy, the treatment burden can extend over months to years. Supportive care is an important complement to the primary treatment plan.
Pelvic floor rehabilitation
Pelvic floor muscle training is evidence-based for improving urinary continence recovery after radical prostatectomy, and should ideally begin before surgery. It is also helpful for managing urinary urgency symptoms during and after SBRT.
Erectile rehabilitation
Post-treatment erectile rehabilitation — including PDE5 inhibitors (sildenafil, tadalafil), vacuum erection devices, and penile injection therapy — is available at major centres. Early initiation (where oncologically appropriate) improves outcomes.
Integrative supportive care
At Chinese cancer centres, integrative approaches — including acupuncture and traditional Chinese medicine (TCM) — may be offered as complementary supportive care during and after prostate cancer treatment. These are positioned as additional quality-of-life support for fatigue, sleep, and emotional wellbeing, not as alternatives to surgery, radiation, or systemic therapy.
ADT side effect management
Patients on androgen deprivation therapy face additional challenges including hot flushes, fatigue, bone density loss, mood changes, and metabolic effects. Structured supportive care programmes — including exercise, nutrition, and where appropriate, bone-protective agents — form part of comprehensive prostate cancer management.
For information on integrative supportive care options available alongside cancer treatment in China, see the supportive care and Traditional Chinese Medicine resources.
Related Guides
Active Surveillance vs Surgery for Prostate Cancer
When watchful waiting is appropriate for prostate cancer — and when intervention cannot be safely deferred.
Prostate Cancer Treatment by Stage
How treatment options differ across localised, locally advanced, and metastatic prostate cancer.
How to Make Cancer Treatment Decisions When Uncertain
A practical framework for navigating conflicting advice and major cancer treatment decisions under uncertainty.
Frequently Asked Questions
Is surgery or SBRT more effective for prostate cancer?
For localised low-to-intermediate risk prostate cancer, surgery and SBRT achieve similar long-term cancer control rates. Clinical trials including PACE-B have demonstrated that SBRT is non-inferior to conventional radiotherapy for disease control. The choice between them is not primarily about which is "more effective" — it is about which approach is most appropriate given a patient's specific risk group, anatomy, baseline symptoms, and quality-of-life priorities.
What are the main side effects of SBRT for prostate cancer?
Acute side effects during SBRT typically include urinary frequency and urgency, and some patients experience bowel irritation. These usually resolve within weeks to months after treatment. Erectile dysfunction may develop gradually over 12–18 months after radiation — later in onset than after surgery. Long-term bowel side effects are a small but real risk and depend partly on baseline bowel function and anatomy. SBRT is generally associated with lower early urinary incontinence than surgery.
What are the main side effects of radical prostatectomy?
Urinary incontinence and erectile dysfunction are the primary side effects of radical prostatectomy. Continence usually recovers in the majority of patients within 3–12 months, particularly with pelvic floor exercises. Erectile function recovery depends on whether nerve-sparing surgery was performed and baseline function before surgery. Surgical risks include bleeding, infection, and anaesthetic risks, which vary with patient fitness and surgical approach (open, laparoscopic, robotic).
Can prostate cancer be treated with SBRT in China?
SBRT for prostate cancer is available at major Chinese cancer and radiotherapy centres equipped with linear accelerators and IGRT (image-guided radiotherapy) capability. Robotic-assisted radical prostatectomy (da Vinci) is also available at leading Chinese tertiary hospitals. An online MDT consultation is the appropriate first step for international patients to understand which approach is available and appropriate for their specific case and staging.
Should I get a second opinion before choosing between surgery and SBRT for prostate cancer?
A second opinion from an MDT (multidisciplinary team) that includes both a urological surgeon and a radiation oncologist is strongly advisable before making this decision. Prostate cancer management is a field where different specialists may emphasise different approaches. An independent review of imaging, biopsy pathology, PSA trajectory, and clinical history allows both surgical and radiation options to be assessed together — rather than seen through a single specialty's lens.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions for prostate cancer should be made in consultation with qualified urological oncologists, radiation oncologists, and medical oncologists who have reviewed the patient's complete clinical records, including imaging, biopsy pathology, and PSA history.
Get an independent assessment before committing to treatment
A structured second opinion from an MDT that includes both a urological surgeon and a radiation oncologist can clarify whether surgery, SBRT, or a combination approach is most appropriate for your specific case — without requiring you to travel first.
Request a case reviewRemote review of your records by specialist urological and radiation oncology teams in China. No travel required to get started.